Exec. Director, Corporate Counsel
Kiniksa Pharmaceuticals
Summary
The Senior Corporate Counsel will serve as a key legal partner to Kiniksa's executive team and Board of Directors, leading SEC reporting, securities compliance, corporate governance, and financing work for a public pharmaceutical company. In this role, you will also work collaboratively on a range of strategic transactions, including collaboration, license, and acquisition agreements, while helping the business manage legal risk.
Job description
This role is based in our Lexington, MA office and requires employees to be onsite five days per week.
Responsibilities
- Draft and prepare periodic '34 Act filings for the Company and work with cross-functional teams to obtain and prepare appropriate disclosure to be included in such filings. Coordinate legal aspects of '34 Act filings.
- Provide legal advice with respect to matters arising under federal securities laws, SEC rules and regulations, securities exchange listing requirements and the rules and regulations of the Sarbanes-Oxley Act
- Support investor relations and corporate communications in connection with public communications and presentations
- Lead the Company's annual meeting process, including interfacing with outside vendors, preparing the Company's proxy statement to its shareholders and running the Company's annual meeting
- Oversee and maintain the Company's insider trading and compliance functions, review and approve draft trading plan agreements and prepare and file Section 16-related filings with the SEC
- Oversee corporate governance matters, including those related to the Company's Board of Directors
- Ensure the corporate organization, including its subsidiaries, remains in good standing
- Advise on transactional matters; prepare, review and negotiate a variety of transaction agreements, including collaboration agreements, license agreements, merger agreements, product/asset acquisitions, option agreements, term sheets, CDAs; perform in-depth due diligence for potential new transactions
- Oversee Company debt and equity financings and the preparation and filing of related '33 Act filings
- Advise on the legal risks accompanying business strategies and decisions
Standout Skills for Impact
- Business-minded pragmatism
- Meticulous attention to detail
- Ownership and initiative
- Trusted, collaborative presence
Qualifications and Experience
- Juris Doctor from an accredited law school
- 6+ years' experience in corporate, M&A, securities or similar transactional law
- Experience working with or at biopharmaceutical/healthcare industry companies
- Ability to work interactively within and across multiple departments and manage priorities effectively
- Excellent oral and written skills with the ability to think critically and work independently
- Ability to work independently as well as with other groups across the business
- Experience managing paralegal or other subordinate personnel, including setting timelines and monitoring progress
Requirements
- Juris Doctor from an accredited law school
- 6+ years' experience in corporate, M&A, securities or similar transactional law
- Experience working with or at biopharmaceutical/healthcare industry companies
- Ability to work interactively within and across multiple departments and manage priorities effectively
- Excellent oral and written skills with the ability to think critically and work independently
- Ability to work independently as well as with other groups across the business
- Experience managing paralegal or other subordinate personnel, including setting timelines and monitoring progress
Company overview
Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs. Founded in 2015 and headquartered in Lexington, Massachusetts, the company focuses primarily on cardiovascular indications and has established itself as a leader in the treatment of recurrent pericarditis. Kiniksa gained FDA approval for ARCALYST®, the first and only FDA-approved treatment for recurrent pericarditis, in March 2021. The company operates globally with offices in the United States, United Kingdom, and Switzerland, and is publicly traded on the NASDAQ Global Market under the ticker symbol KNSA. Kiniksa's pipeline includes clinical-stage assets targeting serious diseases, with a particular emphasis on cardiovascular conditions, and the company maintains a patient-centric approach encapsulated in its 'Every Second Counts' philosophy.